AGIOS PHARMACEUTICALS, INC.

AGIOReported to SECin USCIK 0001439222Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 6. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 6
Form 4 lines at AGIOS PHARMACEUTICALS, INC., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Gheuens SarahChief Medical OfficerOpen-market sell$914,40030,000 sharesAug 6, 2026Gheuens SarahChief Medical Officer$914,400Sell · Aug 6Open-market sell30,000Aug 6, 2026
Backstrom Jay T.—Option exercisenothing paid1,447 sharesJul 10, 2026Backstrom Jay T.nothing paidExercise · Jul 10Option exercise1,447Jul 10, 2026
Backstrom Jay T.—Awardnothing paid1,447 sharesJul 10, 2026Backstrom Jay T.nothing paidAward · Jul 10Award1,447Jul 10, 2026
Gheuens SarahChief Medical OfficerOption exercisenothing paid8,375 sharesJul 2, 2026Gheuens SarahChief Medical Officernothing paidExercise · Jul 2Option exercise8,375Jul 2, 2026
Gheuens SarahChief Medical OfficerOpen-market sell$150,5034,007 sharesJul 2, 2026Gheuens SarahChief Medical Officer$150,503Sell · Jul 2Open-market sell4,007Jul 2, 2026